TGFB1 and hepatocellular carcinoma: A phase I/Ib, open-label, multi-center, dose-escalation ongoing trial is assessing the safety and tolerability of NIS793, a novel anti-TGF-β antibody (Ab) alone or in combination with spartalizumab in advanced refractory solid tumors, including HCC (NCT02947165).